New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:11 EDTTGTX, LGNDTG completes global license agreement with Ligand for IRAK4
TG Therapeutics (TGTX), announced an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. The IRAK4 program is currently in pre-clinical development. Under the terms of the agreement, Ligand will receive an up-front licensing fee of 125k unregistered shares of TG Therapeutics' common stock. In addition, TG will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales.
News For TGTX;LGND From The Last 14 Days
Check below for free stories on TGTX;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
10:30 EDTTGTXTG Therapeutics capitlal raise unlikely, says Roth Capital
Subscribe for More Information
September 15, 2014
14:10 EDTTGTXTG Therapeutics SPA for CLL study earlier than expected, says Ladenburg
Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.
07:03 EDTTGTXTG Therapeutics announces SPA agreement with FDA for Phase 3 trial of TG-1101
Subscribe for More Information
September 9, 2014
09:58 EDTLGNDLigand management to meet with Craig Hallum
Meeting to be held in Milwaukee on September 15 hosted by Craig Hallum.
08:32 EDTLGNDLigand expands license agreement with CURx for Lamotrigine program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use